Genomed Spólka Akcyjna (WSE:GEN)

Market Cap	34.09M -7.2%
Revenue (ttm)	29.58M +21.9%
Net Income	3.07M +56.8%
EPS	2.32 +56.8%
Shares Out	1.32M
PE Ratio	11.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Open	25.80
Previous Close	n/a
Day's Range	25.80 - 25.80
52-Week Range	15.40 - 33.00
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA sequencing and analysis and diagnostics services for congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification of chosen DNA regions, comparison of the sequences, and interpretation of the results by diagnosticians. It also provides various types of DNA sequence analysis, including polymorphism analysis or sequencing ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 56
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GEN

Financial Performance

In 2025, Genomed Spólka Akcyjna's revenue was 29.12 million, an increase of 26.58% compared to the previous year's 23.01 million. Earnings were 3.36 million, an increase of 203.87%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 16, 2026

Data Sources Report a data error